Innoviva (INVA) investor relations material

Business overview and strategy

• Operates a diversified model with royalty-based respiratory assets, a fast-growing specialty therapeutics business, and a strategic healthcare investment portfolio valued at $500 million.

• Royalty business generates about $250 million annually from Breo and Anoro, with strong patent protection into the early 2030s.

• Specialty therapeutics (IST) delivers over $100 million in revenue, growing rapidly, driven by differentiated hospital products.

• Strategic investments target disruptive healthcare assets with high upside and downside protection.

• Maintains flexibility in capital deployment, open to opportunistic royalty acquisitions and synergistic hospital assets.

Specialty therapeutics (IST) growth drivers

• Giapreza leads revenue, benefiting from refreshed commercial strategy and new clinical data expanding use cases.

• Xacduro addresses significant unmet need in resistant Acinetobacter infections, showing strong launch performance.

• Xerava benefits from resistance trends and remains relevant despite being a mature product.

• Zevtera, recently launched, targets Staph aureus bacteremia and is expected to ramp as access expands.

• All IST products have patent protection into the 2030s, with no near-term exclusivity losses.

Commercial and market access strategy

• Hospital launches require navigation of stewardship and P&T committees, but differentiated products ease access.

• Zevtera is positioned as an early option for challenging bacteremia cases, with skin and pneumonia indications seen as upside.

• Giapreza is increasingly used earlier in ICU shock, with expanding adoption in new patient populations.

• Zoliflodacin, pending approval, offers oral therapy for resistant gonorrhea, with commercialization likely to leverage guidelines and a lean sales model.